Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Discontinues Duchenne Hope At Interim Analysis

Anti-Myostatin Approach Disappoints Again

Executive Summary

Roche is to discontinue its RG6206 clinical development program in Duchenne muscular dystrophy after an interim analysis of the Phase II/III SPITFIRE study indicates the compound would be “highly unlikely” to show a clinical benefit.

You may also be interested in...



Sarepta Secures $1.15bn From Roche In Ex-US DMD Gene Therapy Deal

Including upfront payments, half of development costs for SRP-9001, $1.7bn in milestone fees and royalties on sales outside the US, Sarepta pegs deal’s value at $10bn-plus.

Adverse Event Concerns With Solid Biosciences' Candidate DMD Gene Therapy

The US FDA has for the second time placed a clinical hold on Solid Biosciences’ potential gene therapy for Duchenne muscular dystrophy, a move linked to a 70% decline in the company’s share price. The company had reported a serious adverse event in a patient treated with higher doses of the viral vector-delivered gene therapy.

In DMD, Summit Falls Well Short Of Peak It Hoped For

Summit’s utrophin modulator, ezutromid, posted intriguing interim data in January, but failed to meet the primary and all secondary endpoints in a Phase II study. The UK firm discontinued development of ezutromid and will now focus on novel antibiotic candidates.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel